ANDREONE, Pietro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.797
AS - Asia 16.225
EU - Europa 8.956
SA - Sud America 2.411
AF - Africa 414
OC - Oceania 49
Continente sconosciuto - Info sul continente non disponibili 17
Totale 55.869
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.308
SG - Singapore 5.054
CN - Cina 3.327
HK - Hong Kong 3.013
VN - Vietnam 2.022
BR - Brasile 1.829
GB - Regno Unito 1.829
IT - Italia 1.457
FI - Finlandia 1.136
SE - Svezia 1.061
KR - Corea 707
RU - Federazione Russa 706
DE - Germania 626
FR - Francia 378
BG - Bulgaria 371
IN - India 358
PL - Polonia 355
BD - Bangladesh 279
AR - Argentina 235
TR - Turchia 235
CA - Canada 227
ID - Indonesia 227
UA - Ucraina 170
NL - Olanda 166
JP - Giappone 158
MX - Messico 153
ZA - Sudafrica 148
IQ - Iraq 145
AE - Emirati Arabi Uniti 122
ES - Italia 115
AT - Austria 108
LT - Lituania 76
EC - Ecuador 74
IE - Irlanda 74
PK - Pakistan 74
CO - Colombia 73
EG - Egitto 60
CL - Cile 54
MA - Marocco 54
SA - Arabia Saudita 54
UZ - Uzbekistan 51
CZ - Repubblica Ceca 50
PH - Filippine 46
VE - Venezuela 45
BE - Belgio 39
MY - Malesia 39
JO - Giordania 37
DZ - Algeria 36
PY - Paraguay 36
RO - Romania 35
AU - Australia 33
TN - Tunisia 31
KZ - Kazakistan 28
IL - Israele 26
PE - Perù 26
KE - Kenya 24
AZ - Azerbaigian 23
NP - Nepal 23
CR - Costa Rica 22
TH - Thailandia 22
ET - Etiopia 21
AL - Albania 20
CH - Svizzera 20
UY - Uruguay 20
IR - Iran 19
GR - Grecia 18
BO - Bolivia 17
DO - Repubblica Dominicana 16
NO - Norvegia 16
KG - Kirghizistan 15
A2 - ???statistics.table.value.countryCode.A2??? 14
PT - Portogallo 14
NZ - Nuova Zelanda 13
OM - Oman 13
RS - Serbia 13
TW - Taiwan 13
LB - Libano 12
MK - Macedonia 12
BH - Bahrain 11
DK - Danimarca 11
GE - Georgia 11
MD - Moldavia 11
JM - Giamaica 10
LV - Lettonia 10
PR - Porto Rico 10
QA - Qatar 10
EE - Estonia 9
HN - Honduras 9
HU - Ungheria 9
BY - Bielorussia 8
CY - Cipro 7
KH - Cambogia 7
SK - Slovacchia (Repubblica Slovacca) 7
BA - Bosnia-Erzegovina 6
GT - Guatemala 6
LA - Repubblica Popolare Democratica del Laos 6
PA - Panama 6
PS - Palestinian Territory 6
SI - Slovenia 6
SY - Repubblica araba siriana 6
Totale 55.758
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.491
Ashburn 3.353
Singapore 3.257
Hong Kong 2.965
Fairfield 2.373
Chandler 2.080
Helsinki 1.087
London 988
New York 925
Nyköping 857
Woodbridge 848
Houston 783
San Jose 770
Wilmington 754
Hefei 706
Seattle 699
Ho Chi Minh City 640
Cambridge 626
Beijing 603
Los Angeles 589
Seoul 589
The Dalles 565
Hanoi 504
Chicago 484
Ann Arbor 475
San Diego 469
Princeton 372
Council Bluffs 364
Sofia 359
Southend 344
Warsaw 335
Milan 238
Moscow 221
Orem 213
Buffalo 195
Shanghai 194
Salt Lake City 187
Modena 182
Jersey City 176
São Paulo 174
Jakarta 155
Dearborn 152
Jacksonville 149
Dallas 134
Tokyo 118
Redondo Beach 113
Da Nang 110
Istanbul 104
Porto Alegre 97
Frankfurt am Main 93
Lauterbourg 90
Chennai 88
Haiphong 87
Bremen 86
Johannesburg 86
Bupyeong-gu 84
Denver 75
Atlanta 72
Tampa 72
Rome 70
Dublin 68
Vienna 68
Phoenix 67
Munich 66
Elk Grove Village 64
Bologna 63
Brooklyn 62
Amsterdam 59
Norwalk 57
Montreal 56
Toronto 56
Rio de Janeiro 55
Mexico City 53
San Francisco 53
Nuremberg 52
Stockholm 52
Viroflay 51
Manchester 50
Miano 50
Paris 49
Guangzhou 48
Izmir 48
Baghdad 45
Biên Hòa 45
Kent 44
Kilburn 44
Tashkent 44
Augusta 43
Mumbai 43
Des Moines 42
Dhaka 41
Grafing 41
Sterling 41
Boston 39
Poplar 39
Newark 38
Detroit 37
Curitiba 36
Philadelphia 36
San Mateo 36
Totale 39.050
Salva come PNG Salva come JPEG
Nome #
Non-alcoholic steatohepatitis and liver transplantation 519
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 384
Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times 380
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B 348
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 332
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 329
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 320
Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes 319
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 314
Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV 307
A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18. 305
De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients 302
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 298
Missed treatment in an Italian HBV infected patients cohort: HBV RER 289
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals 283
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 283
From current status to optimization of HCV treatment: Recommendations from an expert panel 275
The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease 274
Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study 266
Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials 262
Treatment of nonalcoholic steatohepatitis in adults: present and future 257
Association of nonalcoholic fatty liver disease (Nafld) with peripheral diabetic polyneuropathy: A systematic review and meta-analysis 256
Molecular and functional characterization of CD133+ stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 254
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 250
Global multi-stakeholder endorsement of the MAFLD definition 249
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease 246
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results 242
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 238
Adaptive response in Hepatitis B virus infection 236
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 236
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 235
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” Study. 233
Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing 230
Genetic characterization of adult-onset cryptogenic cholestasis: a prospective multicentre study of 233 patients 229
Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C 227
Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives 227
What to start with in first line treatment of chronic hepatitis B patients: an Italian multicentre observational cohort, HBV-RER study group 221
Characteristics of hepatocellular carcinoma in Italy 220
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 216
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 215
Liver Stiffness measurments using Fibroscan after three months of IFN-based antiviral therapy is unlikely to predict viral response in cirrhotic patients 215
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 215
Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report 215
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study 212
A New Two-Dimensional Shear Wave Elastography for Noninvasive Assessment of Liver Fibrosis in Healthy Subjects and in Patients with Chronic Liver Disease - Eine neue zweidimensionale Shear-Wave-Elastografie zur nicht-invasiven Beurteilung der Leberfibrose bei Gesunden und bei Patienten mit chronischer Lebererkrankung 212
Update on Alcohol and Viral Hepatitis 210
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial 208
Adherence to Mediterranean diet in liver transplant recipients: a cross-sectional multicenter study 208
A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices 206
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 206
Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients 205
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 203
The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives 203
Grazoprevir/elbasvir fixed-dose combination for hepatitis C 202
CD 133+ stem cells for the treatment of end stage liver disease 202
Clinical and serological profile of primary biliary cirrhosis in men 199
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study 199
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 198
Gross pathologic types of hepatocellular carcinoma in Italy. 197
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C 197
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 196
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” 195
Alcohol and viral hepatitis: a mini-review 195
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 194
Working together to tackle HCV infection: Ombitasvir/paritaprevir/ritonavir and dasabuvir combination 194
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis 194
ABT-450: A novel agent for the treatment of CHC genotype 1: Focus on treatment-experienced patients 194
Transjugular intrahepatic portosystemic shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: a real-life, case-control study 191
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation 190
Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C 190
Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis 189
Chronic hepatitis B: Are we close to a cure? 188
Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study 187
La fibrosi epatica: aggiornamenti su fisiopatologia, diagnosi e prognosi 187
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 185
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation 185
Familial intrahepatic cholestasis: New and wide perspectives 184
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants 180
Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods 180
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 179
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 179
Prevalence of and risk factors for fatty liver in the general population of Northern Italy: The Bagnacavallo Study 178
An in-depth psychosocial and biochemical evaluation in transplant recipients for alcoholic liver disease should be planned 177
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients 176
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study 176
A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis 176
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis 176
Risk factors in acute diabetic foot syndrome: analysis of 75 consecutive patients referred to a tertiary center in Modena, Italy 174
Comparing and combining gamma-hydroxybutiric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomized comparative study 174
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study 173
Indomethacin increases 2′,5′-oligoadenylate synthetase release by cultured liver tissue of patients with HCV chronic active hepatitis 172
Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft 172
Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis 172
Atopic dermatitis associated with autoimmune, cardiovascular and mental health comorbidities: a systematic review and meta-analysis 172
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence 171
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 170
Long-term antiviral treatment for recurrent hepatitis C after liver transplantation 170
Central pontine myelinolysis secondary to glycemic variability in type 1 diabetes: a case report and a systematic review of the literature 169
Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods 169
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial 169
Totale 22.460
Salva come PNG Salva come JPEG
Categoria #
all - tutte 290.428
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 290.428
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.090 0 0 0 0 0 0 0 0 0 0 954 136
2021/20225.712 823 485 224 244 116 343 259 413 702 635 802 666
2022/20235.217 696 568 387 500 607 793 72 540 688 31 204 131
2023/20243.483 133 234 153 334 874 178 194 505 99 72 161 546
2024/202512.345 463 84 65 962 2.405 1.716 518 929 1.506 944 1.111 1.642
2025/202623.785 1.254 771 1.937 2.630 3.300 2.823 3.041 1.658 2.592 2.540 1.239 0
Totale 56.391